FrancophonIA/ELRC3.0 huggingface dataset:
English: Further information on Cimzia can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/cimzia.
Estonian: Lisateave Cimzia kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/cimzia.
English: This overview was last updated in 07-2019.
Estonian: Kokkuvõtte viimane uuendus: 07.2019.
English: The European Medicines Agency decided that Cimzia's benefits are greater than its risks and that it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Cimzia kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Other information about Cimzia
Estonian: Muu teave Cimzia kohta
English: Similar results were seen in a study with patients who had not adequately responded to other medicines such as methotrexate.
Estonian: Sarnased tulemused saadi uuringus, milles osalesid teistele ravimitele, nagu metotreksaat, adekvaatselt mittereageerinud patsiendid.
English: The most common side effects with Cimzia (affecting up to 1 in 10 people) are bacterial infections including abscesses (a swollen area where pus has collected), viral infections (including herpes, papillomavirus and influenza), eosinophilic disorders (disorders of eosinophils, a type of white blood cell), leucopenia (low white blood cell counts), nausea (feeling sick), headaches (including migraine), sensory abnormalities (such as numbness, tingling and burning sensation), high blood pressure, hepatitis (liver inflammation) including increased levels of liver enzymes, rash, fever, pain, weakness, itching and reactions at the injection site.
Estonian: Cimzia kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on bakterinfektsioonid, sh abstsessid (mädakolded), viirusinfektsioonid (sh herpes, papilloomiviiruse nakkus ja gripp), eosinofiilsed häired (eosinofiilide ehk vere teatud valgelibledega seotud häired), leukopeenia (leukotsüütide ehk vere valgeliblede vähesus), iiveldus, peavalud (sh migreen), tundlikkushäired (nt tuimus, kirvendus, põletustunne), hüpertensioon (kõrge vererõhk), hepatiit (maksapõletik), sh maksaensüümide suurenenud sisaldus veres, lööve, palavik, valu, nõrkus, kihelus ja süstekoha reaktsioonid.
English: Cimzia is mostly used for conditions that are severe, moderately severe or getting worse, or when patients cannot use other treatments.
Estonian: Cimziat kasutatakse enamasti raskete, mõõdukalt raskete või halvenevate seisunditega patsientidel või kui patsiendid ei saa muid ravimeid kasutada.
English: Cimzia is a medicine that is used in adults to treat the following diseases:
Estonian: Cimziat kasutatakse täiskasvanutel järgmiste haiguste raviks:
English: As for all medicines, data on the use of Cimzia are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Cimzia kasutamise kohta pidevat järelevalvet.
English: Nine main studies involving over 3,000 patients have found Cimzia effective for reducing symptoms of inflammatory conditions.
Estonian: Üheksas põhiuuringus, milles osales üle 3000 patsiendi, leiti, et Cimzia on efektiivne põletikuliste seisundite sümptomite vähendamisel.
English: Side effects reported with Cimzia are carefully evaluated and any necessary action taken to protect patients.
Estonian: Cimzia kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cimzia have also been included in the summary of product characteristics and the package leaflet.
Estonian: Cimzia ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What is Cimzia and what is it used for?
Estonian: Mis on Cimzia ja milleks seda kasutatakse?
English: Pegylation decreases the rate at which the substance is removed from the body and allows the medicine to be given less often.
Estonian: Pegüleerimine vähendab ravimi organismist eemaldamise kiirust ja võimaldab ravimit manustada harvem.
English: A monoclonal antibody is a protein that has been designed to recognise and attach to a specific structure in the body.
Estonian: Monoklonaalne antikeha on valk, mis on välja töötatud ära tundma organismis olevat spetsiifilist struktuuri ja sellega seonduma.
English: Cimzia must not be used in patients with active tuberculosis, other severe infections, or moderate to severe heart failure (inability of the heart to pump enough blood around the body).
Estonian: Cimziat ei tohi kasutada aktiivse tuberkuloosi, muude raskete infektsioonide ega mõõduka kuni raske südamepuudulikkusega patsiendid (kelle süda ei suuda pumbata organismi piisaval hulgal verd).
English: Why is Cimzia authorised in the EU?
Estonian: Miks Cimzia ELis heaks kiideti?
English: For more information about using Cimzia, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Cimzia kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: After training, patients may inject Cimzia themselves if their doctor agrees.
Estonian: Pärast vastavat väljaõpet võivad patsiendid Cimziat endale arsti nõusolekul ise süstida.
English: By blocking TNF-alpha, certolizumab pegol reduces inflammation and other symptoms of the diseases.
Estonian: TNF-α blokeerimisega leevendab tsertolisumaabpegool põletikku ja haiguste muid sümptomeid.
English: A third study compared Cimzia with placebo as well as another medicine called etanercept.
Estonian: Kolmandas uuringus võrreldi Cimziat platseebo ja veel ühe ravimi, etanertseptiga.
English: After this, depending on the condition being treated, patients should continue with 200 mg or 400 mg, given as one or two injections every 2 or 4 weeks.
Estonian: Sõltuvalt ravitavast seisundist jätkavad patsiendid seejärel ravi kas 200 mg või 400 mg annusega, mis manustatakse kas ühe või kahe süstena iga 2 või 4 nädala järel.
English: Patients will be given a reminder card with safety information that they should carry with them.
Estonian: Patsientidele antakse kaasaskantav hoiatuskaart, kus on ravimi ohutusteave.
English: For detailed information on the use of Cimzia in all conditions, see the summary of product characteristics.
Estonian: Üksikasjaliku teabe saamiseks Cimzia kasutamise kohta kõigi nende seisundite korral lugege palun ravimi omaduste kokkuvõtet.
English: These packs will include information on the safety of the medicine.
Estonian: See sisaldab teavet ravimi ohutu kasutamise kohta.
English: The company that markets Cimzia will provide educational packs for doctors who will prescribe Cimzia.
Estonian: Cimzia turustaja annab Cimziat määravatele arstidele teabematerjali.
English: What are the risks associated with Cimzia?
Estonian: Mis riskid Cimziaga kaasnevad?
English: The active substance in Cimzia, certolizumab pegol, reduces the activity of the immune system (the body's defences).
Estonian: Cimzia toimeaine tsertolisumaabpegool vähendab immuunsüsteemi (keha kaitsemehhanism) aktiivsust.
English: The studies included adults with active rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and moderate to severe plaque psoriasis:
Estonian: Uuringutes osalesid aktiivse reumatoidartriidi, aksiaalse spondüloartriidi, psoriaatilise artriidi ja mõõduka kuni raske naastulise psoriaasiga täiskasvanud patsiendid.
English: In patients with active rheumatoid arthritis who had never received DMARDs, treatment with Cimzia led to sustained remission (no detectable disease activity) after 52 weeks of treatment.
Estonian: Aktiivse reumatoidartriidiga patsientidel, kes ei olnud kunagi DMARD-ravimeid kasutanud, saavutati 52-nädalase Cimzia-ravi järel püsiv remissioon (haiguse tuvastatav aktiivsuse puudumine).
English: Cimzia contains the active substance certolizumab pegol.
Estonian: Cimzia sisaldab toimeainena tsertolisumaabpegooli.
English: How does Cimzia work?
Estonian: Kuidas Cimzia toimib?
English: Cimzia can only be obtained with a prescription and treatment should only be started by a specialist doctor who has experience in diagnosing and treating the diseases that Cimzia is used to treat.
Estonian: Ravi sellega tohib alustada üksnes eriarst, kes on kogenud nende haiguste diagnoosimises ja ravis, mille raviks Cimziat kasutatakse.
English: In a study in 879 patients who had never received DMARDs, treatment with Cimzia and methotrexate led to remission in almost 29% of patients (189 out of 655), compared with 15% (32 out of 213) of patients receiving placebo with methotrexate.
Estonian: 879 patsiendiga uuringus, kes ei olnud kunagi DMARD-ravimeid kasutanud, saavutati Cimzia- ja metotreksaatraviga remissioon ligikaudu 29%-l patsientidest (189 patsienti 655st) ning 15%-l platseebot ja metotreksaati kasutanud patsientidest (32 patsienti 213st).
English: It is given by injection under the skin, usually in the thigh or abdomen (belly).
Estonian: Ravimit süstitakse naha alla, tavaliselt reide või kõhtu.
English: The main measure of effectiveness was the number of patients who responded to treatment after 16 weeks, meaning that symptom scores improved by 75% or more.
Estonian: Efektiivsuse põhinäitaja oli 16 nädala järel ravile reageerinud patsientide arv.
English: It is made up of a monoclonal antibody, certolizumab, which has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Estonian: See koosneb monoklonaalsest antikehast tsertolisumaabist, mis on pegüleeritud (seotud keemilise ühendi polüetüleenglükooliga).
English: Also, X-rays showed that joint damage worsened to a lesser extent in patients who received Cimzia.
Estonian: Röntgenuuringud näitasid, et Cimziat kasutanud patsientidel süvenes liigesekahjustus vähem.
English: This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Cimzia is used for.
Estonian: See virgatsaine osaleb põletiku tekitamisel ning selle sisaldus Cimziaga ravitavate haigustega patsientidel on suur.
English: How is Cimzia used?
Estonian: Kuidas Cimziat kasutatakse?
English: For patients receiving Cimzia 400 mg every four weeks 52% saw an improvement.
Estonian: Cimzia 400 mg annust iga nelja nädala järel kasutanud patsientidest saavutati paranemine 52%-l.
English: Treatment starts with a 400-mg dose given as two injections, followed by a further 400-mg dose 2 and 4 weeks later.
Estonian: Ravi algannus on 400 mg kahe süstena, millele järgneb üks 400 mg annus 2 ja teine 4 nädala pärast.
English: For the full list of side effects of Cimzia, see the package leaflet.
Estonian: Cimzia kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Cimzia is available as pre-filled syringes, prefilled pens and dose-dispenser cartridge.
Estonian: Cimziat turustatakse eeltäidetud süstaldena, pen-süstaldena ja annustiga kolbampullidena.
English: Patients on Cimzia 400 mg every two weeks led to 75.8% and 55.4% of patients responding.
Estonian: Cimzia 400 mg annuse manustamisel iga kahe nädala järel tekkis ravivastus vastavalt 75,8%-l ja 55,4%-l patsientidest.
English: In the first study, symptoms were reduced by at least 20% in 57% of patients who received Cimzia (141 out of 246) compared with 9% of patients who received placebo (11 out of 127).
Estonian: Esimeses uuringus vähenesid sümptomid vähemalt 20% võrra 57%-l Cimziat kasutanud patsientidest (141 patsienti 246st) ja 9%-l platseebot kasutanud patsientidest (11 patsienti 127st).
English: Certolizumab pegol has been designed to attach to a messenger protein in the body called tumour necrosis factor alpha (TNF-alpha).
Estonian: Tsertolisumaabpegool on välja töötatud seonduma organismis sisalduva virgatsainega kasvaja α-nekroositeguriga (TNF-α).
English: • For active rheumatoid arthritis that had not improved adequately with disease-modifying antirheumatic drug (DMARD) treatment, two main studies found Cimzia effective when used with methotrexate when compared with placebo (dummy treatment).
Estonian: • Haigust modifitseerivate antireumaatiliste ravimitega (DMARD-ravimid) adekvaatselt mitteparanenud aktiivse reumatoidartriidiga patsientide kahes põhiuuringus leiti, et platseeboga (näiva ravimiga) võrreldes on Cimzia metotreksaadiga koos kasutamisel efektiivne.
English: Cimzia (certolizumab pegol)
Estonian: Cimzia (tsertolisumaabpegool)
English: After 12 weeks of treatment, Cimzia 200 mg every two weeks led to 61% of patients responding and 67% responding with Cimzia 400 mg every two weeks compared with 53% of patients receiving etanercept and 5% of patients receiving placebo.
Estonian: 12-nädalase ravi järel tekkis iga kahe nädala järel Cimzia 200 mg annust kasutanud patsientidest ravivastus 61%-l patsientidest ja iga kahe nädala järel Cimzia 400 mg annust kasutanutest 67%-l patsientidest, samas kui etanertsepti kasutanutest tekkis ravivastus 53%-l ja platseebot kasutanutest 5%-l patsientidest.
English: An overview of Cimzia and why it is authorised in the EU
Estonian: Ülevaade ravimist Cimzia ja ELis müügiloa väljastamise põhjendus
English: • active rheumatoid arthritis (a disease causing inflammation of the joints) when it is used in combination with another medicine, methotrexate, or given alone when treatment with
Estonian: • aktiivne reumatoidartriit (liigesepõletikku põhjustav haigus) kombinatsioonis teise ravimi metotreksaadiga või üksi, kui metotreksaatravi ei ole asjakohane;
English: What benefits of Cimzia have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Cimzia kasulikkus?
English: In the other main study, symptoms were reduced by at least 20% in 59% of patients who received Cimzia (228 out of 388) compared with 14% of patients who received placebo (27 out of 198).
Estonian: Teises põhiuuringus vähenesid sümptomid vähemalt 20% võrra 59%-l Cimziat kasutanud patsientidest (228 patsienti 388st) ja 14%-l platseebot kasutanud patsientidest (27 patsienti 198st).
English: • For psoriatic arthritis, symptoms improved by at least 20% in 58% of patients treated with Cimzia 200 mg every two weeks compared with 24% of patients receiving placebo.
Estonian: • Psoriaatilise artriidi korral paranesid sümptomid vähemalt 20% võrra 58%-l Cimzia 200 mg annust iga kahe nädala järel kasutanud patsientidest ja 24%-l platseebot kasutanud patsientidest.
English: • A study in patients with axial spondyloarthritis showed that symptoms improved by at least 20% after 12 weeks in around 60% of patients treated with Cimzia compared with around 40% of patients receiving placebo.
Estonian: • Aksiaalse spondüloartriidiga patsientide uuringus leiti, et 12-nädalase ravi järel paranesid sümptomid vähemalt 20% võrra 60%-l Cimziaga ravitud patsientidest ja 40%-l platseebot kasutanud patsientidest.
English: Treatment with Cimzia 200 mg every two weeks in the two studies led to 66.5% and 52.6% of patients responding compared with 6.5% and 4.5% of patients receiving placebo.
Estonian: Nendes kahes uuringus leiti, et iga kahe nädala järel manustatava Cimzia 200 mg annusega tekkis ravivastus vastavalt 66,5%-l ja 52,6%-l patsientidest võrreldes 6,5% ja 4,5%-ga platseebot kasutanud patsientidest.
English: • plaque psoriasis, a disease causing red, scaly patches on the skin.
Estonian: • naastuline psoriaas (nahal punaseid ketendavaid laike põhjustav haigus).
English: However, the dose of Cimzia used in this study was higher than the usual dose.
Estonian: Selles uuringus kasutati Cimzia tavaannusest suuremat annust.
English: including ankylosing spondylitis and when the X-ray does not show disease but there are clear signs of inflammation.
Estonian: • aksiaalne spondüloartriit (lülisamba liigestes põletikku ja valu põhjustav haigus), sealhulgas jäigastava (anküloseeriva) spondüliidi korral ja juhul, kui röntgenuuring ei näita haiguskahjustusi, kuid on selged põletikunähud;
English: • In the treatment of moderate to severe plaque psoriasis, Cimzia was compared with placebo in two main studies.
Estonian: • Kahes põhiuuringus võrreldi Cimzia kasutamist platseeboga mõõduka kuni raske naastulise psoriaasi raviks.
English: Timepoints for measurements were 5 minutes, 1 hour, 6 hours, 1 day, 4 days and 15 days.
Estonian: Mõõtmiste ajapunktideks olid 5 minutit, 1 tund, 6 tundi, 1 päev, 4 päeva ja 15 päeva.
English: 7 days from the date/hour of manufacture.
Estonian: 7 päeva valmistamise kuupäevast/tunnist.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Yttrium (
Estonian: TOIMEAINE(TE) SISALDUS Ütrium (
English: INFORMATION IN BRAILLE <Justification for not including Braille accepted>
Estonian: INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) <Põhjendus Braille mitte lisamiseks>
English: Activity may be measured using an ionisation chamber.
Estonian: Aktiivsust saab mõõta ionisatsioonikambri abil.
English: This leaflet was last revised in ().
Estonian: Infoleht on viimati uuendatud ().
English: Intravenous administration should not be protracted over more than 2 hours.
Estonian: Veenisisene manustamine ei tohi kesta üle 2 tunni.
English: However, should this occur, you will receive appropriate treatment from your doctor.
Estonian: Kui see aga siiski juhtub, annab arst teile nõuetekohast abi.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/03/250/001
Estonian: MÜÜGILOA NUMBER EU/1/03/250/001
English: In all cases, it is necessary to ensure that the risks of the radiation are less than from the disease itself.
Estonian: Kõikidel juhtudel tuleb veenduda, et kiiritamisest lähtuv oht on väiksem kui haigusest endast lähtuv.
English: The vial should never be opened and must be kept inside its lead shielding.
Estonian: Viaali ei tohi kunagi avada ja seda tuleb hoida selle pliiümbrises.
English: Usual precautions regarding sterility and radioactivity should be respected.
Estonian: Tuleb järgida tavalisi steriilsuse ja radioaktiivsusega seotud ettevaatusabinõusid.
English: Activity measurements using an ionisation chamber are very sensitive to geometric factors and therefore should be performed only under geometric conditions which have been appropriately validated.
Estonian: Aktiivsuse mõõtmine ionisatsioonikambri abil on väga tundlik geomeetriliste tegurite suhtes ning sellepärast tuleb seda teostada nõuetekohaselt kindlaksmääratud geomeetrilistes tingimustes.
English: Date of the last renewal: 24/03/2008
Estonian: Müügiloa viimase uuendamise kuupäev: 24/03/2008
English: YTRACIS is only to be used by specialists with the appropriate experience.
Estonian: YTRACIS on kasutamiseks ainult nõuetekohase kogemusega spetsialistide poolt.
English: 90Y-yttrium has a half-life of 2.67 days (64.1 hours).
Estonian: Ütriumi 90Y poolestusaeg on 2,67 päeva (64,1 tundi).
English: - Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6).
Estonian: - Tuvastatud või kahtlustatav rasedus või kui rasedus ei ole välistatud (vt lõik 4.6).
English: B CONDITIONS OF THE MARKETING AUTHORISATION
Estonian: B MÜÜGILOA TINGIMUSED
English: If the administration cannot be delayed, a lactating mother should be advised to stop breastfeeding.
Estonian: Kui manustamist ei saa edasi lükata, tuleb imetaval emal soovitada rinnapiimaga toitmine lõpetada.
English: The MAH must ensure that the system of pharmacovigilance, as described in version 7 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Estonian: Müügiloa hoidja peab tagama, et ravimohutuse järelvalve süsteem, nagu on kirjeldatud müügiloa taotluse moodulis 1.8.1 esitatud versioonis 7, on loodud ja toimib enne toote turuletulekut ja toote turustamise ajal.
English: In any case the blood parameters of the patient have to be monitored and the appropriate actions immediately taken if there is evidence of damage to the blood marrow.
Estonian: Kõikidel juhtudel tuleb jälgida patsiendi verenäitajaid ning vererakkude kahjustumise ilmnemisel rakendada viivitamata asjakohaseid vastuabinõusid.
English: It is important to tell your doctor if there is any possibility that you are pregnant.
Estonian: On tähtis teatada arstile igasugusest rasedusvõimalusest.
English: Faecal and urinary elimination is slow: about 13 % of the administered activity is eliminated in 15 days.
Estonian: Väljutumine rooja ja uriini kaudu on aeglane: 15 päevaga väljub umbes 13% manustatud radioaktiivsusest.
English: Radioactive medicinal products should be received, used and administered only by authorised persons in designated clinical settings and receipt, storage, use, transfer and disposal are subject to the regulations and appropriate licences of the competent authorities.
Estonian: Radioaktiivseid ravimpreparaate on lubatud vastu võtta, kasutada ja manustada ainult volitatud isikute poolt selleks kohandatud haiglatingimustes ning nende vastuvõtmine, säilitamine, kasutamine, ümberpaigutamine ja hävitamine peab toimuma kooskõlas pädevate asutuste määruste ja asjakohaste lubadega.
English: Like all medicines, YTRACIS can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka YTRACIS põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: Radioactive medicinal products should be prepared by the user in a manner which satisfies both radiation safety and pharmaceutical quality requirements.
Estonian: Radioaktiivsete ravimpreparaatide valmistamine kasutaja poolt peab toimuma viisil, mis rahuldab nii kiirgusohutuse kui farmatseutilise kvaliteedi nõudeid.
English: You will be asked to stop breast-feeding.
Estonian: Teil palutakse imetamine lõpetada.
English: The dosimetry estimates were based on a rat biodistribution study and the calculations were effected in accordance with MIRD/ICRP 60 recommendations.
Estonian: Need dosimeetrilised hinnagud põhinevad rottide biojaotuse uuringul ning arvutused on teostatud kooskõlas MIRD/ICRP 60 soovitustega.
English: What YTRACIS looks like and contents of the pack
Estonian: Kuidas YTRACIS välja näeb ja pakendi sisu
English: Organ Adult male 70 kg
Estonian: Täiskasvanud naine 57 kg
English: At 1 and 24 hours, blood radioactivity decreases from 11 % to 0.14 % of the administered activity.
Estonian: Vere radioaktiivsus kahaneb 1 ja 24 tunni vahemikus 11%-lt 0,14%-ni manustatud aktiivsusest.
English: Organ doses (mGy/MBq injected) and effective dose (Sv/GBq injected).
Estonian: Organite doosid (mGy/MBq süstitud) ja efektiivdoosid (Sv/GBq süstitud).
English: Batch N°: {XXXXX}
Estonian: Maht: {Z} ml Akt.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of the first authorisation: 24/03/2003
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 24.03.2003
English: These complexes are rapidly eliminated by the kidneys.
Estonian: Need kompleksid väljutatakse organismist kiiresti neerude kaudu.
English: Pharmacotherapeutic group: Not applicable ATC code: Not applicable
Estonian: ATC kood: Ei ole kohaldatav
English: It is important that all glassware, syringe needles etc, used for the preparation of the radiolabelled medicinal product are thoroughly cleaned to ensure freedom from such trace metal impurities.
Estonian: On tähtis, et kõik radiomärgistatud ravimpreparaadi valmistamisel kasutatavad klaastarvikud, süstlanõelad jne oleksid sellise jälgsaaste vältimiseks põhjalikult puhastatud.
English: (GBq : GigaBecquerel, Becquerel is the unit in which radioactivity is measured).
Estonian: gigabekerell; bekerell on radioaktiivsuse mõõtmise ühik).
English: Particular care should be taken when administering radioactive medicinal products to children and adolescents.
Estonian: Eriliti ettevaatlik peab olema radioaktiivsete ravimpreparaatide manustamisel lastele ja noorukitele.
English: The following information is intended for medical or healthcare professionals only: For detailed information refer to the Summary of Product Characteristics of YTRACIS.
Estonian: Järgnev informatsioon on mõeldud ainult meditsiinipersonalile või tervishoiutöötajale: Üksikasjalikku teavet lugege YTRACIS'e “Ravimi omaduste kokkuvõttest”.
English: The chelating efficacy is greatest immediately or within one hour of exposure when the radionuclide is circulating in or available to tissue fluids and plasma.
Estonian: Kelaatimise efektiivsus on suurim esimese ekspositsioonijärgse tunni jooksul, kui radionukliid veel ringleb või on kättesaadav koevedelikes ja plasmas.